Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04315584
Recruitment Status : Recruiting
First Posted : March 19, 2020
Last Update Posted : March 24, 2020
Sponsor:
Information provided by (Responsible Party):
Bijoy Kundu, University of Virginia

Brief Summary:
The purpose of this pilot study will be to conduct a clinical trial using a time-of-flight PET scanner and MRI scanner to test an improved method for differentiating tumor recurrence from radiation necrosis in glioblastoma patients. We will attempt to do so by performing a static and dynamic FDG-PET scan, a static and dynamic FDOPA-PET scan, and a multiparametric MRI scan - then comparing the results with surgical pathology and static FDG-PET scans. We hypothesize that the new quantitative kinetic analytical methods using FDOPA in combination with FDG will provide crucial functional information to distinguish recurrent tumors from treatment-induced radiation changes in patients with treated brain neoplasms. This is important for improving patient outcomes by allowing treating physicians to more accurately tailor treatments. Furthermore, dynamic FDG and FDOPA PET will be combined with high resolution anatomic and physiologic MRI in order to develop a multimodal multiparametric approach for differentiating tumor recurrence from treatment effect.

Condition or disease Intervention/treatment Phase
Glioblastoma Procedure: Positron Emission Tomography Procedure: Computed Tomography Procedure: Multiparametric Magnetic Resonance Imaging Scan Radiation: Fludeoxyglucose F-18 Radiation: fluorine F 18 fluorodopa Early Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. The primary objective will be to evaluate the diagnostic accuracy of Dynamic PET imaging in differentiating tumor recurrence from treatment effect (radiation necrosis or pseudoprogression) in patients previously treated with chemo-radiation therapy for primary high grade gliomas. This will be accomplished by examining the concordance between the Dynamic PET imaging prediction and the criterion standard, which will be based on either surgical pathology or an integrated clinical/MRI determination within a 3-6 month interval after Dynamic PET imaging.

SECONDARY OBJECTIVES:

I. The diagnostic accuracy of Static PET imaging, advanced MRI, and advanced MRI + Dynamic PET imaging in differentiating tumor recurrence from radiation-induced necrosis in high grade glioma patients will be examined in the same exact way as just outlined for Dynamic PET imaging.

OUTLINE:

Subjects receive 18FDG (first scan) and (18)F-FDOPA (2-14 days from the first scan) intravenously (IV) slowly over a period of 15-20 seconds and then undergo dynamic PET scans over a period of 60-90 minutes. CT scans on the subjects are performed before the dynamic PET scans for 5 minutes. Subjects also undergo MRI brain examinations just prior to the FDOPA scan over a period of 1 hour, which includes T1 weighed, T1 weighted contrast enhanced, T2 weighted, Diffusion tensor imaging, MR spectroscopy, and Dynamic susceptibility contrast perfusion weighted (DSC-PWI) imaging.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: All 5 study subjects will undergo the same procedures.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: FDG and FDOPA PET Demonstration of Functional Brain Abnormalities
Estimated Study Start Date : March 15, 2020
Estimated Primary Completion Date : December 20, 2023
Estimated Study Completion Date : June 20, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Diagnostic
Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
Procedure: Positron Emission Tomography
Undergo PET/CT Scans
Other Names:
  • PET
  • PET Scan
  • Positron Emission Tomography Scan
  • Medical Imaging, Positron Emission Tomography

Procedure: Computed Tomography
Undergo PET/CT Scans
Other Names:
  • CT
  • CT Scan
  • Computerized Axial Tomography
  • CAT
  • CAT scan

Procedure: Multiparametric Magnetic Resonance Imaging Scan
Undergo a multiparametric MRI scan
Other Names:
  • mpMRI
  • multiparametric MRI

Radiation: Fludeoxyglucose F-18
IV (intravenous) administration of radiotracer
Other Names:
  • FDG
  • 18 FDG
  • fludeoxyglucose F 18
  • 2-F18-fluoro-2-deoxy-D-glucose
  • 2-F18-fluoro-2-deoxyglucose

Radiation: fluorine F 18 fluorodopa
IV (intravenous) administration of radiotracer
Other Names:
  • 18F-6- L-fluorodopa
  • 18F-DOPA
  • 18F-FDOPA
  • 3,4-dihydroxy-6-(18)F-fluoro-l-phenylalanine
  • L-6-[ 18F]fluoro-3, 4-dihydroxyphenylalanine
  • (18)F-FDOPA




Primary Outcome Measures :
  1. Quantitative parametric maps indicating differences in rates of glucose and amino acid uptake (Ki) obtained from dynamic FDG and FDOPA scans respectively. [ Time Frame: Up to 6 months ]
    Will be derived from PET/CT scan imaging.

  2. Quantitative parametric maps indicating differences in details (d) components of the wavelet transform analysis, d6 and d8, based on established tumor feature criterions. [ Time Frame: Up to 6 months ]
    Will be derived from MRI brain scan imaging.

  3. Semi-quantitative standardize uptake value (SUV) parametric maps based on static PET scans (last 20 minutes of the dynamic PET scans). [ Time Frame: Up to 6 months ]
    Will be derived from PET/CT scan imaging.

  4. MRI brain metrics [ Time Frame: Up to 6 months ]
    Including anatomic assessment based on T1, T2, and contrast enhanced T1 weighted imaging, MR spectroscopy data (choline, creatinine, and N-acetyl acetate peak integrals and ratios), MR perfusion data (relative cerebral blood volume), and diffusion tensor imaging data (apparent diffusion coefficient, fractional anisotropy)

  5. Surgical pathology or 3-6 month interval multidisciplinary clinical evaluation. [ Time Frame: Up to 6 months ]
    To be compared with the imaging analyses for comparing ability to differentiate tumor recurrence from radiation necrosis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18
  • Known or suspected recurrent malignant brain tumors
  • Radiographic worsening reported on MRI shortly (within 3 months) after completion of radiation and temozolomide therapy
  • Able to lie flat and/or still for a minimum of 60 minutes
  • Willingness and ability to comply with scheduled visits and study procedures
  • Patients who have a clinical indication for a PET-CT
  • If female, patient must be postmenopausal or surgically sterile

Exclusion Criteria:

- Conditions that preclude a clinical brain FDG PET study, including: Consumption of liquids with sugar and/or caffeine prior to the study, Blood glucose levels over 150 mg/mL, Eating or drinking calories of any type within 4 hours of radiotracer injection, Hyperinsulinemia, Patients who for any reason cannot tolerate lying supine for 60 minutes

  • Conditions that preclude a FDOPA PET study, including: Consuming a diet that is NOT low in protein after the previous evening meal
  • Tumor located in the striatum
  • Changes in medication (new prescriptions or change in dosages) between visits 1 and 2
  • Pregnant, nursing, or lactating
  • Women of childbearing potential (premenopausal female capable of becoming pregnant), which also includes:

women on oral, injectable, or mechanical contraceptives, women who are single, women whose male partners have been vasectomized or whose male partners have received or are utilizing mechanical contraceptive devices

  • Weight > 450 lbs
  • Known allergic reactions to 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) and Fluorine-18 fluorodeoxyglucose (18F-FDG)
  • Confirmation that study eligibility criteria have not been met between visits 1 and 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04315584


Contacts
Layout table for location contacts
Contact: Bijoy Kundu, PhD (434) 924-0284 bkk5a@virginia.edu

Locations
Layout table for location information
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22903
Contact: Florence Yan    434-243-6768    fty5jf@hscmail.mcc.virginia.edu   
Principal Investigator: Bijoy Kundu, PhD         
Sponsors and Collaborators
University of Virginia
Investigators
Layout table for investigator information
Principal Investigator: Bijoy Kundu, PhD University of Virginia
Layout table for additonal information
Responsible Party: Bijoy Kundu, Bijoy Kundu, PhD, University of Virginia
ClinicalTrials.gov Identifier: NCT04315584    
Other Study ID Numbers: HSR190096
First Posted: March 19, 2020    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bijoy Kundu, University of Virginia:
glioblastoma
PET
CT
multiparametric MRI
brain imaging
tumor recurrence
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Glioblastoma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Deoxyglucose
Fluorodeoxyglucose F18
Dihydroxyphenylalanine
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents